Bortezomib vs no bortezomib: Treatment‐related death ‐ Bortezomib versus no bortezomib (different background therapy or other agents)
It is very uncertain whether bortezomib changes treatment‐related death ‐ Bortezomib versus no bortezomib (different… compared with no bortezomib (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Bortezomib vs no bortezomib Treatment‐related death ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma It is very uncertain whether bortezomib changes treatment‐related death ‐ Bortezomib versus no bortezomib (different… compared with no bortezomib (very low certainty). Bortezomib for the treatment of multiple myeloma (2016) · Cochrane Headline outcomes only | OR 0.73 [0.36, 1.48] | 3 studies · 1652 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.